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Summary Cell lines derived from A-MuLV induced thymic lymphomas in BALB/c and C57BL/6 mice were
analysed for their in vivo and in vitro potential of growth. Despite their immunogenicity, cell lines of BALB/c
origin readily grew in syngeneic recipients. On the contrary, all cell lines of C57BL/6 origin failed to grow in
immunocompetent hosts even though they were able to form tumours in immunosuppressed syngeneic mice.
Among C57BL/6 lymphoma cells progression toward a more malignant phenotype was observed in TB6-3
cells, and in their derived clones, after several in vitro passages. This event was accompanied by the in vitro
loss of requirement for exogenous growth factor(s) when tumorigenic TB6-3 cells were plated at high density.
Moreover, culture medium from fully malignant TB-3 cells was mitogenic for mature T-lymphoma cells
suggesting the involvement of an autocrine mechanism in the control of cell proliferation. Apparently, the
viral oncogene (v-abl) is not directly involved in malignant progression since no differences between non-
tumorigenic and tumorigenic cells could be detected in A-MuLV integration patterns, v-abl specific mRNA
expression, and P160gag-abl production.
Abelson murine leukaemia virus (A-MuLV) is a replication-
defective retrovirus which originated through recombination
between the replication-competent Moloney leukaemia virus
(M-MuLV) and specific sequences (c-abl) of the normal
mouse genome (Abelson & Rabstein, 1970). The only pro-
duct coded by A-MuLV is a hybrid protein (P160gag-abl)
which possesses a tyrosine kinase activity (Sefton et al.,
1981) and is considered responsible for the oncogenic poten-
tial of A-MuLV (Witte et al., 1978).
A-MuLV transforms in vitro lymphoid cells (Rosenberg et
al., 1975) as well as fibroblasts (Scher & Siegler, 1975), while
in vivo induces lymphomas which are most frequently of the
pre-B cell phenotype (see review by Risser, 1982). However,
it is possible to induce thymic lymphomas by injecting the
virus intrathymically (Cook, 1982). Previous studies (Cook,
1982, 1985; Risser et al., 1985; Saggioro et al., 1985, 1986;
Scott et al., 1986; D'Andrea et al., 1987) indicated that cells
derived from A-MuLV induced thymic lymphomas are very
immature and possess phenotypic features different from
those usually expressed by pre-B lymphoid cells involved in
A-MuLV induced lymphomas.
The rapid induction of lymphomas in vivo and the direct
transformation of fibroblasts in vitro suggest that A-MuLV
can induce malignant transformation in a single step fashion
by means of its tyrosine kinase activity. However, in some in
vitro systems, A-MuLV integration and expression does not
necessarily result in an indefinite ability to grow (Rosenberg
& Baltimore, 1976; Whitlock et al., 1983) and, following A-
MuLV injection, it has been demonstrated that only a few of
the infected bone marrow cells are transformed (Green et al.,
1987).
As part of a larger study aimed to characterize the A-
MuLV target cells within the thymic tissue, we report here
the in vivo and in vitro growth properties of A-MuLV
transformed cell lines obtained by injecting the virus directly
in the thymus of newborn BALB/c and C57BL/6 mice. Cell
lines of C57BL/6 origin showed a limited in vitro growth
ability and lack of tumorigenicity in syngeneic immuno-
competent hosts soon after their establishment in vitro from
primary tumours. After continuous in vitro growth, progres-
sion towards a more malignant phenotype was observed in
one cell line (TB6-3). No substantial differences in A-MuLV
integration patterns, v-abl specific mRNA expression, and
P160gag-abl could be detected before and after progression in
TB6-3 cells implying that the activity of a single oncogene
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(v-abl) might not be sufficient for full malignant
transformation.
Materials and methods
Mice
BALB/c and C57BL/6 (B6) mice were originally purchased
from The Jackson Laboratory (Bar Harbor, ME, USA) or
Charles River Laboratories (Calco, Como, Italy) and main-
tained in our colony for several generations by sister
x brother matings.
Virus
ABC-1, a pre-B A-MuLV transformed cell line (Teich et al.,
1979), was the source of the A-MuLV(M-MuLV) complex.
Three to 4 x 106 ABC-I cells were injected s.c. in syngeneic
BALB/c mice and from the transplanted tumour mass, a cell
free extract was prepared as already described (Chieco-
Bianchi et al., 1974). The A-MuLV titre (3.5 x 103 FFU/ml)
was determined by focus formation on NIH 3T3 fibroblasts
(Scher & Siegler, 1975); the helper M-MuLV was titrated by
UV-XC plaque assay (Rowe et al., 1970).
Cell lines and culture medium
TA-2, TA-3 (H-2d), and TB6-1, TB6-2, TB6-3 (H-2b) cell
lines were established in vitro from primary thymic lympho-
mas induced by injecting A-MuLV intrathymically (i.t.) in
newborn BALB/c (H-2d) and B6 (H-2b) mice respectively
(Saggioro et al., 1986; D'Andrea et al., 1987). YC8 (H-2d)
(Leclerc et al., 1972), MBL-2 (H-2b) (Glynn et al., 1968) and
TB-5 (H-2d) (Saggioro et al., 1986) are established cell lines
derived from M-MuLV induced lymphomas.
All lymphoma cell lines were cultured in complete medium
consisting of Dulbecco-MEM (GIBCO, Europe, Glasgow,
UK) supplemented with 2x 10-3M L-glutamine, 3 x 10-2M
HEPES, 5 x 10-5M 2-mercaptoethanol, antibiotics and 10%
heat-inactivated foetal calf serum (FCS) (GIBCO).
Western blot analysis
Five million cells were lysed directly in Laemmli buffer and
subjected to SDS polyacrylamide gel electrophoresis
(Laemmli, 1970); Western blot analysis was carried out
according to the method of Towbin et al. (1979) and as
previously described (Saggioro et al., 1986). After transfer,
the nitrocellulose blot was rinsed and incubated with an anti
M-MuLV serum (Lot. No. 71S/161, Office of Program and
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Resources and Logistics, NCI, Bethesda, MD, USA); specific
binding was revealed by 1251-labelled protein A (Amersham
International, Amersham, UK). The dried blot was exposed
to Kodak X-Omat R film with intensifying screen.
Southern and Northern blot analysis
High molecular weight DNA was prepared by cell lysis,
proteinase K digestion, extraction with phenol-chloroform,
and precipitation with ethanol (Maniatis et al., 1982). DNA
(10pg) was digested with the restriction enzyme EcoRI and
electrophoresed in 0.8% agarose gels. Total RNA was
extracted with guanidine-hydrocloride and fractionated
(10Ig) by 1.2% formaldehyde/agarose gel electrophoresis.
DNA and RNA gels were transferred to Nytran membranes
(Scheleicher & Schuell, Keene, NH) according to the tech-
nique of Southern (1975). Filters were hybridized overnight
to a nick translated probe (Rigby et al., 1977) as already
described (D'Andrea et al., 1987). The 2.0kb v-abl specific
probe used in this study was derived from the pAB3Sub3
plasmid (Goff et al., 1980) with the use of the restriction
enzymes Sma I and Hind III.
Generation of virus specific cytotoxic T lymphocytes
Cytotoxic T lymphocytes (CTL) were generated in vitro by
using a mixed leukocyte tumour cells culture (MLTC) as
previously described (Collavo et al., 1978). Briefly, 20 x 106
responder spleen cells and 4 x 106 mitomycin C treated
(40 jg per 5 x 106 cells perml) stimulator cells were cultured
in a total volume of 15ml complete medium. Responder cells
were spleen cells of mice that did not develop tumour after
injection of A-MuLV lymphoma cells or had undergone
complete tumour regression after Moloney murine sarcoma
virus (M-MSV) injection (Collavo et al., 1978); either TB6-3
and TA-2 cells or the transplantable MBL-2 and YC8
lymphoma cells were used as stimulator cells, for the B6 and
BALB/c mouse system, respectively. The cytotoxic activity of
CTL was tested as previously described (Collavo et al.,
1978), and its specificity analysed using normal Concanava-
lin A (ConA) blasts as negative controls.
Conditioned media
Conditioned media (CM) from TA-2 and TB6-3 cell lines
were obtained by growing the cells (5 x 105 ml-1) in medium
containing 1% FCS. After 3 days, the media were centri-
fuged at 400g to pellet the cells and clarified from the virus
at 100,000g. The supernatants were then filtered through a
0.2jm Millipore membrane.
Tritiated thymidine (3H-TdR) incorporation assay
For the determination of the DNA-synthesis rate, 2 x 103
cells/well were incubated in the presence of scalar doses of
CM in medium containing 1% FCS when using the TB-5
cell line, or 10% FCS when using the CTL-L cell line and
thymocytes. After 48-72h, 3H-TdR (specific activity:
1 mCiml- ) was added and left overnight; the cells were
then harvested and the incorporation of 3H-TdR determined
using a beta-counter.
Results
Viral characterization of cell lines derivedfrom A-MuLV
thymic lymphomas
Cell lines derived from A-MuLV induced thymic lymphomas
in BALB/c (TA-2 and TA-3) and B6 mice (TB6-1, TB6-2
and TB6-3) were first analysed for A-MuLV integration,
expression, and production although the short latent period
of tumour appearance and the rapid establishment of in vitro
cell lines (D'Andrea et al., 1987), suggested a direct involve-
ment of the acute transforming A-MuLV in these tumours.
Three to four bands corresponding to acquired abl sequences
were detected in all cell lines through Southern blot analysis
(D'Andrea et al., 1987) and an approximately equal amount
of abl mRNA was detected in the cell lines as shown in
Figure 1. The data obtained by Northern blot analysis were
confirmed by Western blot experiments in which the gag-abl
specific protein was detected along with the structural pro-
teins of the helper M-MuLV, using an anti M-MuLV serum
(Figure 2). In fact, all cell lines were productively infected by
the A-MuLV(M-MuLV) complex, since culture supernatants
tested for the presence of infectious virus were able to induce
foci in NIH 3T3 fibroblasts as well as plaques in the UV-XC
test (data not shown).
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Figure 1 Northern blot analysis of A-MuLV lymphoma cells.
RNA was extracted from the cell lines soon after their establish-
ment in vitro. Total RNA (10jug) from tumorigenic TA-2 and
non-tumorigenic TB6-l, TB6-2 and TB6-3 cells was separated by
formaldehyde/agarose gels and hybridized with a v-abl specific
probe.
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Figure 2 Detection of P160gag-abl polyprotein in A-MuLV lym-
phoma cell lines by Western blot analysis. Cellular proteins,
transferred to nitrocellulose sheets, were immunodecorated with
an anti M-MuLV serum which recognizes the gag portion of
P160gag-abl hybrid protein. Malignant TA-2 and TA-3 were of
BALB/c origin, non-tumorigenic TB6-l, TB6-2 and TB6-3 were
of B6 origin, and TB-5 cells, included as control, were derived
from a M-MuLV induced lymphoma in BALB/c mouse.
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Phenotypic characterization showed that all cells derived
from either BALB/c and B6 mice were negative for T-
lymphocyte antigens (Thy 1.2, Lyt 1.2 and Lyt 2.2) and for
cytoplasmic IgM usually expressed in pre-B cells, indicating
that intra-thymic inoculation of A-MuLV gives rise to
lymphoid tumours of a very immature phenotype (D'Andrea
et al., 1987).
Tumorigenicity of A-MuLV transformed cell lines
The tumorigenic potential of the A-MuLV lymphoma cell
lines was examined by injection s.c. adult syngeneic mice
with different cell doses. As shown in Table I, the BALB/c
cell lines (TA-2 and TA-3) were highly tumorigenic since
even a low dose (5 x 103 cells) induced tumours in 80 to
100% of recipient mice. On the contrary, cells of B6 origin
(TB6-1, TB6-2 and TB6-3) were not able to grow in
syngeneic recipients even when injected at high dose (107
cells). However, when TB6-3 cells were inoculated in subleth-
ally irradiated (5.5Gy) B6 mice, they invariably killed the
host within a short period of time (14 days). In addition,
when B6 mice, which did not exhibit any tumour growth
after syngeneic lymphoma cell inoculation, were challenged
with a lethal dose (105) of MBL-2 cells derived from a M-
MuLV induced lymphoma no tumour growth was observed
(data not shown). Similarly, no tumour development was
noticed when the few BALB/c mice which escaped death
after injection of a low dose of TA-3 cells (see Table I), were
reinoculated with a lethal dose (106) of the same tumour
cells. These findings suggest that both BALB/c and B6 A-
MuLV lymphoma cell lines are immunogenic in syngeneic
recipients.
H-2 antigen expression and cytotoxic T-lymphocyte generation
Since rejection of syngeneic tumour cells carrying viral
antigens is mainly due to the cytotoxic activity of T lympho-
cytes, we investigated whether the transplantation of A-
MuLV lymphoma cells could induce a virus-specific cellular
response. Cytotoxic T lymphocytes (CTL) recognize foreign
antigens, such as viral polypeptides, on cell surfaces only in
association with class I histocompatibility antigens (Zinker-
nagel & Doherty, 1975). Hence, we first established that A-
Table I Tumorigenicity of A-MuLV lymphoma cells
No. cells No. pos. micel MSTa
Cell origin injected no. injected (days)
BALB/c: TA-2 106 7/7 18+3
105 4/4 20+3
5x103 5/5 28+4
103 4/5 26+3
TA-3 106 5/5 26+7
105 4/5 31+14
104 8/8 34+ 15
5x103 4/5 41+9
103 1/5 30
B6: TB6-1 5x 106 0/9
106 0/2
105 0/4
TB6-2 107 0/3
5 x 106 0/8
106 0/7
TB6-3 107 1/5 22
5 x 106 0/5
106 0/6
105 0/4
MuLV transformed cells in common with control splenocytes
expressed detectable amounts of H-2 determinants using
specific anti-class I monoclonal antibodies in indirect
immunofluorescence (data not shown). We then prepared
mixed leukocyte tumour cell cultures (MLTC) using spleen
cells from B6 mice, which did not develop tumour after
injection of 107 TB6-3 cells as effectors, and TB6-3 cells as
stimulators. As shown in Table II, CTL generated in this
way were able to lyse TB6-3 cells efficiently; no cytotoxicity
against normal ConA blasts was observed. Similarly, when
spleen cells from a BALB/c mouse, which did nQt develop
tumour after TA-2 injection, were used as effectors in an
MLTC, CTL able to kill virus infected TA-2 cells were
obtained.
As already mentioned, A-MuLV is a defective virus whose
envelope antigens are specified by the helper M-MuLV.
Since all our A-MuLV infected cell lines carry and express the
helper M-MuLV, it is reasonable to suppose that the vigor-
ous immune response evoked by tumour cells is mainly
directed against M-MuLV coded antigens. Tumour induction
by M-MSV (naturally associated with the M-MuLV helper
virus) represents a widely used and highly reproducible
experimental system for studying the immune reactivity to
MuLVs (Leclerc et al., 1972). Thus, to further assess the
viral specificity of the host immune response, effector spleen
cells from M-MSV regressor B6 or BALB/c mice (Collavo et
al., 1978), were stimulated with MBL-2 (H-2b) or YC8 (H-
2d) (M-MuLV lymphoma cell lines) respectively. CTL gener-
ated in this way were able to lyse A-MuLV as well as M-
MuLV lymphoma cells efficienctly (see Table II). These
results confirm that A-MuLV transformed cells are highly
immunogenic and are readily recognized and lysed by virus
specific CTL.
In vivo and in vitro progression of lymphoma cells
In an attempt to determine whether it was possible to obtain
B6 cell variants able to grow in adult syngeneic immuno-
competent mice, a few clones were derived from the non-
tumorigenic TB6-3 cells by limiting dilution. When tested for
oncogenicity, all four TB6-3 clones grew and killed the host
although they exhibited a different degree of malignancy (the
mean survival time of injected mice varying from 20 to 59
days) (Table III). Furthermore, when the TB6-3 cells, which
were maintained continuously in culture during clone isola-
tion, were reinoculated into untreated mice they were able to
kill 75% of injected mice in a short period of time (20 days)
(Table III). It should be mentioned that no phenotypic
changes were observed in TB6-4 and TB6-2 cells which did
not become tumorigenic after continuous in vitro growth.
The acquisition of growth capacity in vivo by TB6-3 cells and
its clones was not accompanied by substantial changes in A-
MuLV integration patterns (Figure 3A) or v-abl specific
mRNA expression (Figure 3B). Moreover, no loss of suscep-
tibility to lysis in vitro by specific CTL was observed (data
not shown). Thus, the increased tumorigenicity observed
after in vitro passages could imply a cellular progression
toward a more malignant phenotype not linked to additional
A-MuLV integrations or to variations in immunogenicity
and immunosensitivity.
On the other hand, the malignant progression of the TB6-
3 lymphoma cell line observed in vivo was accompanied by
an in vitro loss of requirement for exogenous growth
factor(s) (Table III), a property also shared by TA-2 cells. In
fact, after 7-9 months of growth in vitro, TB6-3 cells, which
were sensitive to the FCS concentration soon after their
establishment in vitro, were afterwards able to grow in 1%
FCS medium, like TA-2 cells. A further analysis of TB6-3
and TA-2 cell lines showed that their growth in vitro was
dependent on the cell concentration since optimal growth at
low serum concentration (1-2%) was achieved only when at
least 105 cells/well were plated; less than 50% of cell growth
was observed at 104 cells/well in presence of the same FCS
concentration (Figure 4). This raises the possibility that A-
TB6-3 106 8/8b 14+ 5
Tumorigenicity was tested in adult BALB/c and B6 mice by s.c.
injection of graded doses of A-MuLV lymphoma cells. Mice which
did not develop tumour after two months were considered negative.
aMean survival time+ I s.d. bB6 mice irradiated with a sublethal dose
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Table II Specific CTL induction by A-MuLV transformed cells
% Specific 51Cr releasea at
effector/target cell ratio of
Effector
Spleen cells from TB6-3
immune B6 mouse'
Spleen cells from TA-2
immune BALB/c mouse'
Spleen cells from M-MSV
immune B6 mouse
Stimulator Target
TB6-3 TB6-3
TB6-3 B6 Blasts
TA-2 TA-2
TA-2 BALB/c Blasts
MBL-2
MBL-2
MBL-2
MBL-2
Spleen cells from M-MSV
immune BALB/c mouse
TB6-1
TB6-2
TB6-3
MBL-2
50:1 17:1 6:1 2:1
67 68 50 38
0 0 0 0
68 71 58 39
15 15 14 10
43
41
70
52
68
52
57
YC8 TA-2
YC8 TA-3
YC8 YC8
22
53
65
52
52
40
37
14
34
62
40
34
26
17
9
22
34
28
21
21
11
Generation of H-2 restricted CTL against A-MuLV infected cells in BALB/c and B6 mice was
obtained by injecting the mice with A-MuLV infected cells or M-MSV cell-free preparations. Normal
ConA blasts were included, as controls, in each set of experiments. aCalculated in a 4h incubation
assay; bB6 mouse which did not develop tumour after injection of 107 TB6-3 cells; cBALB/c mouse
which did not develop tumour after injection of 103 TA-2 cells.
MuLV transformed cell lines release a factor(s) to sustain
their own growth as suggested by Sporn & Todaro (1980)
for similar observations on given cell lines.
Mitogenic activity of conditioned media
In order to see whether A-MuLV lymphoma cells produce
and secrete a mitogenic factor(s), serial dilutions of con-
ditioned media (CM) from TB6-3 and TA-2 cell lines were
tested. First, we analysed whether cells from these lines
release normal lymphokines such as IL-1 and IL-2. Any
attempt to induce stimulation of growth (evaluated by 3H-
TdR incorporation) in normal, freshly isolated thymocytes
(Krakauer et al., 1982) and in the IL-2 dependent CTL-L
cell line (Gills et al., 1978) grown in the presence of CM
from TB6-3 and TA-2 cultures, was unsuccessful (data not
shown). On the contrary, when CM from TB6-3 and TA-2
cultures were tested on the M-MuLV lymphoma TB-5 cell
line, which is not responsive to either IL-1 or IL-2 (data not
shown), a significant increase in DNA synthesis was
observed (Table IV).
These results support the hypothesis that A-MuLV trans-
formed cell lines might specifically release factor(s), different
from IL-1 and IL-2, which not only stimulates their own
growth but is able to induce DNA synthesis in other
lymphoma cells.
Discussion
During tumour progression many genotypic (Nowell, 1986)
and/or phenotypic (Nicolson, 1987) changes may occur
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Table III In vivo and in vitro growth properties of TB6-3 cells and
their derived clones
Percentage
ofgrowthb
No. cells No. pos. mice/ MSTa in presence of
Cells injected no. injected (days) 1% FCS
TB6-3c 5x 106 0/5 36
Clone Bd 5 x106 5/10 20+3 86
Clone C 5 x106 10/10 21+7 N.D.
Clone D 5 x106 8/10 20+9 90
Clone E 5 x 106 3/3 59+5 82
TB6-3e 5 x 106 6/8 20+5 87
.Tumorigenicity of TB6-3 cells and their derived clones were tested
by s.c. injection in adult syngeneic mice. aMean survival time+ 1 s.d.; bl05 cells were plated in 96 microwell plates and the percentage of
growth calculated taking as 100% the incorporation of 3H-TdR by
each cell culture in the presence of 10% FCS; CTB6-3 cells tested
after 2 months from their establishment in vitro. dTB63 clones were
originally derived from the non-tumorigenic TB6-3 cell lines and
tested as soon as massive cultures were available; eTB6-3 cells tested
after 8-10 months of continuous in vitro growth.
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Figure 3 Southern and Northern blot analysis of the non-
tumorigenic TB6-3 cells and its derived tumorigenic clones. The
specific v-abl probe was used to hybridize both EcoRI digested
DNA (10pi) extracted from primary TB6-3 cells and its derived
clones (a) as well as total RNA (10 ig) from TB6-3 cells and its
clones B and E (part b).
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Figure 4 Growth curves of TB6-3 and TA-2 cells as a function
of FCS concentration. The cells were seeded at different cell
density (105:- A; 3 x I04:0 O; 104:- 0) in micro-
well plates. After 48h, 25 'iCi 3H-TdR were added and left
overnight. The radioisotope incorporation was evaluated with a
beta-counter. The percentage of growth, for each cell concent-
ration, was calculated taking as 100% the growth of the cells in
the presence of 10% FCS.
through still poorly defined mechanism(s) (Schirrmacher,
1985).
In our system various factors, inherent to both host
immune response and growth potential of the cells, appear
to contribute to the tumorigenic behaviour of A-MuLV
lymphoma cells. These cells, like most virus transformed
cells, are highly immunogenic and able to stimulate the host
immunity. In B6 mice, which are known to be highly
responsive to A-MuLV antigens (Risser et al., 1985), the lack
of in vivo growth of TB6-3 cells is likely to be attributable to
a virus-specific cell mediated immune response rather than to
the inability of cells to grow, since the same cells were able
to kill all the immunosuppressed animals. However, after a
long period of in vitro cultivation, the TB6-3 cell line as well
as its clones were able to grow in immunocompetent hosts.
Apparently, the malignant cells were not variants which had
lost their immunogenic potential since they were still H-2
positive and behaved in vitro as targets for specific CTL
(data not shown).
Progression to a more malignant phenotype was accompa-
nied by loss of requirement for exogenous growth factor(s)
when cells were plated at high density (Figure 4). Thus, the
tumorigenic potential of A-MuLV transformed cells is
related not only to the immune response of the animal but
also to their growth potential. This could also be the case for
Table IV Growth stimulation of TB-5 cells by CM of TB6-3 and
TA-2 cells in the presence of 1% FCS
3H-thymidine incorporation
(cpm+ Is.d.)
CM Dilution 48h 72h
4022+265 4756+810
TB6-3 1:2 6721+ 168 11356+917
1:4 5160+221 7396+732
TA-2 1:2 8126+675 13752+506
1:4 8001+1236 7702± 1708
Growth stimulation of TB-5 cells by conditioned media (CM) of
TB6-3 and TA-2 cells was tested by plating 5 x 103 cells/well in 96
microwell plates in the presence of 1% FCS and graded concent-
rations of CM. After 48 and 72h, 25MCi 3H-TdR are added; cells
were harvested after an overnight incubation and the radioisotope
incorporation evaluated with a beta-counter.
TA-2 cells, (a BALB/c derived cell line), which were highly
malignant despite their immunogenicity (see Tables I and II).
The cell concentration dependent fashion of growth in
vitro suggests the involvement of an autocrine mechanism of
proliferative stimulation (Sporn & Todaro, 1980). The acti-
vation of autocrine loops has been demonstrated in other
spontaneous and induced haematopoietic tumours (Gordon
et al., 1984; Hays et al., 1984; Haas et al., 1986) as well as in
fibroblasts transformed by A-MuLV (Twardzik et al., 1982;
Gebhardt et al., 1986). On the contrary, three recent studies
provide evidence for non-autocrine mechanisms of growth in
mast cells and myeloid cells infected with A-MuLV (Cook et
al., 1985; Pierce et al., 1985; Oliff et al., 1985). In our system
the finding that conditioned media (CM) from the TA-2 and
TB-3 cell lines are able to stimulate the DNA synthesis of
other lymphoma cell lines, suggests that these cell lines might
produce and release their own growth factor(s), different
from IL-l or IL-2.
The possibility that the observed malignant progression is
due to v-abl modifications seems unlikely since no significant
differences in A-MuLV integration patterns, v-abl specific
mRNA expression, or P160gag-abl production could be
detected between tumorigenic and non-tumorigenic cells.
Taken together these data suggest that, following A-
MuLV infection and immortalization, cells progress toward
a more transformed and malignant phenotype, which appar-
ently is not brought about by direct viral oncogene activity.
This progression was relatively slow in cells of B6 haplotype
and allowed us to monitor the system, whereas in BALB/c
derived cells the oncogenic potential was reached in a shorter
time.
It is possible that the observed malignant progression is
the result of selection of a minor subpopulation already
present in the primary thymic lymphoma, with a capacity for
unrestricted growth. However, the genomic stability observed
in v-abl integration and expression patterns (Figure 3A,B)
argttes against a clonal selection hypothesis of variants
among TB6-3 cells. The in vitro progression could be the
result of secondary changes which further alter the in vivo
and in vitro growth properties of the whole cell population.
The role of the abl oncogene in promoting these secondary
events is unknown and might not be due to genetic
alterations.
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